Trials / Recruiting
RecruitingNCT07467564
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 184 (estimated)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupilumab | This study will not administer any treatment, only observe the treatment as prescribed in real world clinical practice. |
Timeline
- Start date
- 2026-02-24
- Primary completion
- 2027-05-24
- Completion
- 2027-05-24
- First posted
- 2026-03-12
- Last updated
- 2026-03-12
Locations
1 site across 1 country: United Arab Emirates
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07467564. Inclusion in this directory is not an endorsement.